Skip to main content
. 2021 Jan 21;12:498. doi: 10.1038/s41467-020-20603-4

Fig. 4. Comparison of pathological diagnosis and methylation class prediction.

Fig. 4

Classifier validation using sarcoma cases enrolled in the MNP2.0, PTT2.0, INFORM or NCT MASTER trials. Institutional diagnosis (left) and classifier prediction (right) of the 322 cases that received a methylation class prediction ≥0.9. The institutional diagnosis of 263 cases matched the classifier prediction (concordant; grey bars). In 59 cases the classifier prediction differed from institutional diagnosis, with 29 cases reclassified in favour of the methylation class prediction (discrepant—reclassified; blue bars), 26 cases where molecular validation analysis was inconclusive (discrepant; light blue bars), and four cases with a misleading classifier result (discrepant – misleading; red bar).